Skip to content

LBRX LBRX EPS (Diluted)

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.31+9.2%
Alkermes logo
AlkermesALKS
-$0.40-408%
MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
-$1.34+95.4%
Alto Neuroscience logo
Alto NeuroscienceANRO
-$0.80-42.9%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0.60+1,100%
Opko Health logo
Opko HealthOPK
-$0.07+30.0%

Other financials

Income statement

See full
Net income-$19.1M-259%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$874.06M+159%
Enterprise value$556.86M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's EPS (diluted)?
LBRX (LBRX) reported EPS (diluted) of -$0.67 in Q1 2026.
How has LBRX's EPS (diluted) changed year-over-year?
LBRX's EPS (diluted) increased by 95.5% year-over-year, from -$14.79 to -$0.67.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.